Evotec (EVO) Competitors $3.88 -0.07 (-1.77%) Closing price 04:00 PM EasternExtended Trading$3.98 +0.10 (+2.55%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVO vs. PCVX, MTSR, KRYS, PTCT, ARWR, ACLX, KYMR, PTGX, CRNX, and ZLABShould you be buying Evotec stock or one of its competitors? The main competitors of Evotec include Vaxcyte (PCVX), Metsera (MTSR), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Evotec vs. Its Competitors Vaxcyte Metsera Krystal Biotech PTC Therapeutics Arrowhead Pharmaceuticals Arcellx Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Zai Lab Evotec (NASDAQ:EVO) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability. Do analysts recommend EVO or PCVX? Evotec currently has a consensus price target of $7.00, suggesting a potential upside of 80.41%. Vaxcyte has a consensus price target of $106.25, suggesting a potential upside of 147.96%. Given Vaxcyte's stronger consensus rating and higher possible upside, analysts plainly believe Vaxcyte is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Vaxcyte 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has stronger valuation and earnings, EVO or PCVX? Evotec has higher revenue and earnings than Vaxcyte. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$862.40M1.60-$212.18MN/AN/AVaxcyteN/AN/A-$463.93M-$4.11-10.43 Which has more volatility and risk, EVO or PCVX? Evotec has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Do institutionals and insiders hold more shares of EVO or PCVX? 5.8% of Evotec shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to EVO or PCVX? In the previous week, Vaxcyte had 5 more articles in the media than Evotec. MarketBeat recorded 9 mentions for Vaxcyte and 4 mentions for Evotec. Vaxcyte's average media sentiment score of 0.99 beat Evotec's score of 0.27 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 1 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is EVO or PCVX more profitable? Vaxcyte has a net margin of 0.00% compared to Evotec's net margin of -20.14%. Vaxcyte's return on equity of -16.85% beat Evotec's return on equity.Company Net Margins Return on Equity Return on Assets Evotec-20.14% -16.94% -8.14% Vaxcyte N/A -16.85%-15.92% SummaryVaxcyte beats Evotec on 10 of the 14 factors compared between the two stocks. Get Evotec News Delivered to You Automatically Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVO vs. The Competition Export to ExcelMetricEvotecMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.38B$2.61B$6.02B$10.45BDividend YieldN/A57.78%5.73%4.82%P/E RatioN/A22.5685.1227.24Price / Sales1.60752.53589.92133.47Price / CashN/A26.3325.7730.18Price / Book1.335.3612.676.76Net Income-$212.18M$33.06M$3.32B$276.59M7 Day Performance-1.02%0.71%0.50%0.86%1 Month Performance11.82%10.16%9.42%8.17%1 Year Performance31.08%-0.86%79.11%43.66% Evotec Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOEvotec2.1623 of 5 stars$3.88-1.8%$7.00+80.4%+25.8%$1.38B$862.40M0.004,827Gap DownPCVXVaxcyte2.467 of 5 stars$41.21-3.4%$106.25+157.8%-61.7%$5.54BN/A-10.03160Analyst ForecastMTSRMetseraN/A$52.50+1.2%$55.75+6.2%N/A$5.45BN/A0.0081KRYSKrystal Biotech4.4603 of 5 stars$180.57-1.5%$209.00+15.7%+3.4%$5.31B$290.52M36.70210Analyst RevisionPTCTPTC Therapeutics3.2925 of 5 stars$64.80-0.9%$69.00+6.5%+69.4%$5.19B$1.76B9.301,410Analyst RevisionARWRArrowhead Pharmaceuticals4.0949 of 5 stars$37.50+3.8%$43.14+15.0%+96.6%$4.99B$3.55M-29.30400Gap DownACLXArcellx2.2012 of 5 stars$84.38-0.8%$114.31+35.5%+0.0%$4.72B$107.94M-24.6780Analyst RevisionKYMRKymera Therapeutics1.5538 of 5 stars$57.55-0.6%$61.26+6.5%+33.0%$4.14B$47.07M-16.58170Insider TradePTGXProtagonist Therapeutics1.6891 of 5 stars$64.14-1.1%$68.36+6.6%+75.6%$4.03B$434.43M91.63120Analyst ForecastInsider TradeCRNXCrinetics Pharmaceuticals3.7491 of 5 stars$41.68+2.0%$74.45+78.6%-16.4%$3.85B$1.04M-10.14210ZLABZai Lab2.7927 of 5 stars$33.31-1.3%$56.35+69.2%+23.3%$3.77B$398.99M-16.331,869News CoveragePositive News Related Companies and Tools Related Companies Vaxcyte Alternatives Metsera Alternatives Krystal Biotech Alternatives PTC Therapeutics Alternatives Arrowhead Pharmaceuticals Alternatives Arcellx Alternatives Kymera Therapeutics Alternatives Protagonist Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives Zai Lab Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVO) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. ...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy Wall Street is piling into the “Debasement Trade”Wall Street is piling into what insiders are calling the “Debasement Trade” — and according to former Goldman ...Stansberry Research | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredWhat the hell is going on, America?America’s $37.5 trillion debt spiral, soaring deficits, and repeated credit downgrades are exactly what Porter...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
